Collaboration Agreements

1,978 Contracts & Agreements

Collaboration agreements include contracts that define joint initiatives between a company and other parties.

Browse Collaboration Agreements by Industry

Aerospace & Defense (1 contract from 1 company)
Air Freight & Logistics (2 | 1)
Auto Components (3 | 2)
Automobiles (1 | 1)
Biotechnology (1,202 | 300)
Chemicals (8 | 3)
Communications Equipment (2 | 1)
Construction & Engineering (1 | 1)
Consumer Finance (5 | 2)
Diversified Consumer Services (4 | 3)
Electrical Equipment (21 | 5)
Electronic Equipment, Instruments & Components (5 | 1)
Energy Equipment & Services (4 | 3)
Entertainment (3 | 2)
ETFs (9 | 2)
Food Products (1 | 1)
Health Care Equipment & Supplies (111 | 42)
Health Care Providers & Services (7 | 7)
Health Care Technology (4 | 3)
Hotels, Restaurants & Leisure (1 | 1)
Household Durables (3 | 1)
Household Products (1 | 1)
Independent Power & Renewable Electricity Producers (1 | 1)
Interactive Media & Services (1 | 1)
Internet & Direct Marketing Retail (1 | 1)
Life Sciences Tools & Services (26 | 13)
Machinery (1 | 1)
Media (1 | 1)
Metals & Mining (6 | 3)
Oil, Gas & Consumable Fuels (5 | 3)
Personal Products (2 | 1)
Pharmaceuticals (236 | 117)
Semiconductors & Semiconductor Equipment (9 | 6)
Software (4 | 4)
SPACs, Investment, & Acquisition Companies (11 | 5)
Specialty Retail (1 | 1)
Unassigned Industry (271 | 124)

Recent Contracts

Research and Collaboration Agreement Between Jiangsu Alphamab Biopharmaceuticals Co., Ltd and Arrivent Biopharma, Inc (ArriVent Biopharma, Inc., Filed With SEC on August 14, 2024)
First Amendment to Collaboration and License Agreement, dated as of May 14, 2024, by and between the Registrant and Torii Pharmaceuticals Co., Ltd (Verrica Pharmaceuticals Inc., Filed With SEC on August 14, 2024)
Amendment No. 4 to the Research Collaboration Agreement, dated May 2, 2024, by and between Nkarta, Inc. and CRISPR Therapeutics AG (Nkarta, Inc., Filed With SEC on August 13, 2024)
Amendment No. 3 to the Research Collaboration Agreement, dated April 3, 2024, by and between Nkarta, Inc. and CRISPR Therapeutics AG (Nkarta, Inc., Filed With SEC on August 13, 2024)
Amendment No. 1 to Collaboration and License Agreement by and between the Company and Everest Medicines II (HK) Limited, dated as of July 2, 2024 (Kezar Life Sciences, Inc., Filed With SEC on August 13, 2024)
Collaboration and License Agreement dated May 3, 2024 by and among GB002, Inc., Gossamer Bio 002 Ltd. and Gossamer Bio, Inc. on the one hand and CHIESI Farmaceutici S.p.A and... (Gossamer Bio, Inc., Filed With SEC on August 12, 2024)
First Amended and Restated Collaboration Agreement, dated April 2, 2024, by and between Adimab, LLC and Leap Therapeutics, Inc (LEAP THERAPEUTICS, INC., Filed With SEC on August 12, 2024)
Amendment to Research Collaboration and License Agreement with Giiant Pharma, Inc. dated August 2, 2024 (Neuralstem, Inc., Filed With SEC on August 12, 2024)
FNAIT Collaboration Agreement, dated April 9, 2024, by and between Momenta Pharmaceuticals, Inc. and Rallybio IPA, LLC (Rallybio Corp, Filed With SEC on August 8, 2024)
Amendment No. 4 to the Option, License and Collaboration Agreement between Arcus Biosciences, Inc. and Gilead Sciences, Inc., dated May 10, 2024 (Arcus Biosciences, Inc., Filed With SEC on August 8, 2024)
Third Amendment to Collaboration and Commercialization Agreement, by and between the Subsidiary and Ascensia Diabetes Care (Senseonics Holdings, Inc., Filed With SEC on August 8, 2024)
Collaboration Agreement, dated May 6, 2024, between the Registrant and The Swiss Group for Cancer Research SAKK (INTENSITY THERAPEUTICS, INC., Filed With SEC on August 8, 2024)
Amendment No.1 to the Collaboration and License Agreement effective as of June 28, 2024 by and between CytomX Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc (CytomX Therapeutics, Inc., Filed With SEC on August 8, 2024)
Amendment No. 1 to Amended and Restated Collaboration and License Agreement, dated May 17, 2024, by and between Allogene Therapeutics, Inc. and Notch Therapeutics (Canada) Inc (Allogene Therapeutics, Inc., Filed With SEC on August 7, 2024)
Collaboration Agreement between Rani Therapeutics, LLC and ProGen Co., Ltd. dated June 17, 2024 (Rani Therapeutics Holdings, Inc., Filed With SEC on August 6, 2024)
Addendum to Collaboration and License Agreement between argenx BV and Zai Auto Immune (Hong Kong) Limited dated June 30, 2024 (Zai Lab Ltd, Filed With SEC on August 6, 2024)
First Amendment to Collaboration Agreement, by and between Registrant and Neurocrine Biosciences, Inc., dated April 3, 2024 (Voyager Therapeutics, Inc., Filed With SEC on August 6, 2024)
Collaboration Agreement, dated as of April 4, 2024, by and between the Company and BiBo Biopharma Engineering Co., Ltd (89bio, Inc., Filed With SEC on August 5, 2024)
Collaboration and License Agreement, by and between the Registrant and Xyphos Biosciences, Inc. dated April 30, 2024 (Poseida Therapeutics, Inc., Filed With SEC on August 5, 2024)
Fifth Amendment to License and Collaboration Agreement between Alkermes Pharma Ireland Limited and Biogen International GmbH (as successor to Biogen Swiss Manufacturing GmbH),... (Alkermes plc., Filed With SEC on July 24, 2024)
Collaboration Agreement (Hypersolar, Inc., Filed With SEC on July 23, 2024)
Collaboration Agreement (Kensington Capital Acquisition Corp., Filed With SEC on July 11, 2024)
Amendment to Collaboration and License Agreement between Innovent Biologics (Suzhou) Co. Ltd. and AnHeart Therapeutics Inc, dated November 30, 2022 (Panacea Acquisition Corp, Filed With SEC on June 20, 2024)
Collaboration and License Agreement between Innovent Biologics (Suzhou) Co. Ltd. and AnHeart Therapeutics Inc, dated May 31, 2021 (Panacea Acquisition Corp, Filed With SEC on June 20, 2024)
First Amendment to Supply and Collaboration Agreement dated as of May 31, 2024 by and between the Company and DaVita Inc (CHF Solutions, Inc., Filed With SEC on June 6, 2024)
Amendment No. 1, dated June 26, 2023, to Collaboration Agreement, dated July 19, 2021, by and between Proteomedix AG and New Horizon Health Limited (Blue Water Vaccines Inc., Filed With SEC on June 5, 2024)
Collaboration Agreement, dated July 19, 2021, by and between Proteomedix AG and New Horizon Health Limited (Blue Water Vaccines Inc., Filed With SEC on June 5, 2024)
Amendment No. 1 to Strategic Collaboration Agreement, by and between the Registrant and GlaxoSmithKline LLC, dated May 20, 2024 (Tempus AI, Inc., Filed With SEC on June 5, 2024)
Collaboration and Research Support Agreement, dated May 17, 2024, by and between Tivic Health Systems, Inc. and The Feinstein Institutes for Medical Research (Tivic Health Systems, Inc., Filed With SEC on May 22, 2024)
Second Amendment to the Collaboration and License Agreement, dated February 7, 2024, by and among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc (Poseida Therapeutics, Inc., Filed With SEC on May 14, 2024)
First Amendment to the Collaboration and License Agreement by and between the Company and Gilead Sciences, Inc., dated (MACROGENICS INC, Filed With SEC on May 9, 2024)
Amendment Number Two to Collaboration and License Agreement, dated March 29, 2024, by and between Arcturus Therapeutics, Inc. and Seqirus Inc (Arcturus Therapeutics Holdings Inc., Filed With SEC on May 8, 2024)
Amendment No. 2 to Amended and Restated Clinical Collaboration and Supply Agreement, by and between the Company and Novartis Institutes for BioMedical Research, Inc., dated March... (Olema Pharmaceuticals, Inc., Filed With SEC on May 8, 2024)
Letter Agreement Amending the 2021 Collaboration and License Agreement between the Registrant and Glaxo Wellcome UK Ltd. dated March 11, 2024 (Alector, Inc., Filed With SEC on May 8, 2024)
Collaboration, Option and License Agreement, dated as of March 5, 2024, by and between Merus N.V. and Gilead Sciences, Inc (Merus N.V., Filed With SEC on May 8, 2024)
Side Letters to Master Collaboration Agreement, dated as of March 20, 2018, between Prothena Biosciences Limited and Celgene Switzerland LLC (Prothena Corp plc, Filed With SEC on May 8, 2024)
Amendment No. 4 to the Collaboration and License Agreement, dated as of March 28, 2024, by and between CytomX Therapeutics, Inc. and Amgen, Inc (CytomX Therapeutics, Inc., Filed With SEC on May 8, 2024)
Fifth Amendment to Collaboration and License Agreement by and between the registrant and Bristol-Myers Squibb Company, dated March 14, 2024 (Repare Therapeutics Inc., Filed With SEC on May 7, 2024)
Clinical Trial Collaboration and Supply Agreement by and between MSD International Business GmbH and IDEAYA Biosciences, Inc., dated as of March 8, 2024 (IDEAYA Biosciences, Inc., Filed With SEC on May 7, 2024)
1st Amendment to License and Collaboration Agreement, by and between the Registrant and Daiichi Sankyo Company, Limited dated January 2, 2024 (Esperion Therapeutics, Inc., Filed With SEC on May 7, 2024)